Clinical Trial Search

Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…

Primary: Self-reported Pain Scores Using 100m Visual Analog Scale 0-100 Pain Score. — 6.4; 12.3 mm

Primary: Change in Severity of Lesions(Degree of Reticular, Erythematous and Ulceration) by Using Piboonniyom REU Severity Score — 2.15; 0.73 Scores on a scale — p=0.004

Primary: Pain — 0; 4; 4.4 units on a scale

Primary: Percent Change From Baseline to Two Weeks in Symptoms and Signs of Oral Lichen Planus (OLP) — -22; 0; -17; 0 percent change

Primary: Change in Oral Sensitivity — -4.5; -6.0 score on a scale

Primary: Physician Global Assessment (PGA) of Skin Overall Response — 5; 5; 0; 0 Participants

Primary: Serum Leptin Level — 13.23; 4.20 ng/ml

Primary: Change in Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) — 11.0 score on a scale

Primary: Maximum Tolerated Dose — 8 J/cm2

Primary: Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) at Week 16 — 50.0; 21.9 percentage of participants — p=0.0129

Primary: Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP — 44.0; 58.2; 37.5; 23.1 percentage of participants

Primary: Change in Patient-Reported Itch — -0.33 units on a scale

Primary: Best Overall Response Rate (BORR) — 36.4 percentage of participants

Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30

Primary: Average Scores for VLS Clinical Signs Present At Baseline, 3, 6 and 12 Months After the Last Treatment as Assessed by the Investigators — 1.85; 0.65; 0.65; 0.73 score on…

Primary: Change in Lichen Planopilaris Activity Index (LLPAI) — -42.9; -66.7 percentage of change from baseline — p=0.014

Primary: Change in SkinDEX-29 Score — -16.83; -5.92 score on a scale — p=0.007

Primary: Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment — 2.36; 2.83; 1.9; 2.58 unit on histologic grade scale — p=0.048

Primary: Percentage of Participants With a Response as Assessed by the 273-point Oral Mucositis Rating Scale (OMRS) Who Received Topical Clobetasol 0.05% Oral Rinse for Oral…

Primary: OMI-20 Total Score Change From Baseline to Day 3 — 0.0; 0.0 score on a scale

Primary: Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm. — 13; 10; 12 patients with sustained response — p=0.404

Primary: Gingival Index (GI) — 1.04; 1.01 units on a scale — p=<0.05

Primary: Percentage of Participants With ITCH4 at Week 12 — 35.7; 40.0 percentage of participants — p=0.737

Primary: Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses — 7 Participants

Primary: Incidence and / or Severity of Oral Mucositis — 19; 3 Grade 3-4 oral mucositis — p=0.05

Primary: Relative Percent Change in Total Lesion Area After 6 Months on Study — -20.6; -17.1 percentage change

Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980

Primary: Percentage Change in Psoriasis Area and Severity Index (PASI) — -5.6; -7.6; -0.3; -12.7 percentage of change in PASI index score — p=0.89

Primary: Number and Percentage of Lesions That Were Stained Positive — 29; 28 lesions — p=0.005